BACKGROUND: Type 5 phosphodiesterase (PDE5) expression in the normal and pathological prostate is controversial. OBJECTIVES: This study aimed at identifying the cell type/s, if any, expressing PDE5 in human healthy or pathological prostate sections in order to further validate the rationale of PDE5 inhibitor (PDE5i) treatment of benign prostatic hyperplasia (BPH) and their safety in the treatment of erectile dysfunction following prostate cancer (PCa) surgery. MATERIALS AND METHODS: By immunohistochemical analysis, we studied PDE5 expression in tissue microarrays containing sections obtained from healthy, BPH, and PCa samples. RESULTS: Our results showed that PDE5 is barely expressed in the epithelial or stromal compartment of normal human prostates, but it is highly expressed in the stromal compartment of BPH sections. We also found that a low but significant number of PCa samples (22%) expressed PDE5 in the epithelial cancer cells but not in stromal cells and that such expression was not correlated with the tumor aggressiveness, according to their Gleason score. DISCUSSION AND CONCLUSION: PDE5 overexpression in the stromal compartment of BPH samples supports the rationale of PDE5 as a target in lower urinary tract symptoms of BPH. PDE5 expression in a significant percentage of PCa samples but the lack of correlation with the Gleason score suggests that this enzyme is not correlated with tumor aggressiveness; however, a role of PDE5 in the minimal residual disease of PCa cannot be excluded.

Bisegna, C., Gravina, G.l., Pierconti, F., Martini, M., Larocca, L., Rossi, P., et al. (2019). Regulation of PDE5 expression in normal prostate, benign prostatic hyperplasia, and adenocarcinoma. ANDROLOGY, 8(2), 427-433 [10.1111/andr.12695].

Regulation of PDE5 expression in normal prostate, benign prostatic hyperplasia, and adenocarcinoma

Martini M.;Rossi P.;Grimaldi P.;Dolci S.;Di Stasi S.;Jannini E. A.
2019-08-21

Abstract

BACKGROUND: Type 5 phosphodiesterase (PDE5) expression in the normal and pathological prostate is controversial. OBJECTIVES: This study aimed at identifying the cell type/s, if any, expressing PDE5 in human healthy or pathological prostate sections in order to further validate the rationale of PDE5 inhibitor (PDE5i) treatment of benign prostatic hyperplasia (BPH) and their safety in the treatment of erectile dysfunction following prostate cancer (PCa) surgery. MATERIALS AND METHODS: By immunohistochemical analysis, we studied PDE5 expression in tissue microarrays containing sections obtained from healthy, BPH, and PCa samples. RESULTS: Our results showed that PDE5 is barely expressed in the epithelial or stromal compartment of normal human prostates, but it is highly expressed in the stromal compartment of BPH sections. We also found that a low but significant number of PCa samples (22%) expressed PDE5 in the epithelial cancer cells but not in stromal cells and that such expression was not correlated with the tumor aggressiveness, according to their Gleason score. DISCUSSION AND CONCLUSION: PDE5 overexpression in the stromal compartment of BPH samples supports the rationale of PDE5 as a target in lower urinary tract symptoms of BPH. PDE5 expression in a significant percentage of PCa samples but the lack of correlation with the Gleason score suggests that this enzyme is not correlated with tumor aggressiveness; however, a role of PDE5 in the minimal residual disease of PCa cannot be excluded.
Online ahead of print
Rilevanza internazionale
Articolo
Esperti anonimi
Settore BIO/16
Settore MED/13
English
Con Impact Factor ISI
phosphodiesterase 5, prostate, benign prostatic hyperplasia, prostatic cancer.
Bisegna, C., Gravina, G.l., Pierconti, F., Martini, M., Larocca, L., Rossi, P., et al. (2019). Regulation of PDE5 expression in normal prostate, benign prostatic hyperplasia, and adenocarcinoma. ANDROLOGY, 8(2), 427-433 [10.1111/andr.12695].
Bisegna, C; Gravina, Gl; Pierconti, F; Martini, M; Larocca, L; Rossi, P; Grimaldi, P; Dolci, S; Di Stasi, S; Jannini, Ea
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
Andrology PDE5 PCa proofs andr_12695.pdf

accesso solo dalla rete interna

Tipologia: Versione Editoriale (PDF)
Licenza: Copyright dell'editore
Dimensione 8.13 MB
Formato Adobe PDF
8.13 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2108/219164
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 3
  • ???jsp.display-item.citation.isi??? 3
social impact